GlassScriptPhysician profile
Sara E Welch
NPI 1861689606
$9,326.75
in general payments reported to CMS, 2019-2025
37 companies · $1,543 in 2025
The $1,543 reported for 2025 was more than what 89% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,164 · 2022: $1,754 · 2023: $2,391 · 2024: $1,475 · 2025: $1,543.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,378 · Travel and Lodging: $921 · Education: $110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,378.32 |
| Travel and Lodging | $920.92 |
| Education | $109.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim International Gmbh | $1,295.92 | 2023 | |
| Inspire Medical Systems, INC. | $1,281.22 | 2021-2025 | Inspire |
| Jazz Pharmaceuticals INC. | $1,221.43 | 2021-2025 | |
| Novo Nordisk INC | $844.19 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Regeneron Healthcare Solutions, INC. | $467.01 | 2021-2025 | Evkeeza, Praluent |
| Esperion Therapeutics, INC. | $449.51 | 2021-2025 | Nexletol |
| Axsome Therapeutics, INC. | $442.24 | 2023-2025 | Sunosi |
| Abbott Laboratories | $416.05 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Novartis Pharmaceuticals Corporation | $375.04 | 2021-2025 | |
| Amgen INC. | $343.55 | 2021-2025 | Repatha, Repatha |
| Lilly USA, LLC | $273.92 | 2021-2025 | Mounjaro, Zepbound |
| Harmony Biosciences LLC | $266.02 | 2021-2025 | Wakix |
| Corcept Therapeutics | $204.26 | 2022-2024 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $195.92 | 2024-2025 | Jardiance |
| Amarin Pharma, INC. | $149.37 | 2021-2023 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Welch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.